$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks. Here are some top stocks in the sector climbing on drug trial and earnings news: $Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap. $Ligand Pharmaceuticals (LGND.US)$gained 23%...
The drop in share price and EPS indicates potential unresolved challenges within the company. Despite the insider purchases, investors are advised to ensure they are buying into a high quality business before making any decisions.
The chance to purchase National Vision Holdings at a favorable price has vanished. With future negative growth uncertainty, it might be time to lessen portfolio risk. The high beta of the stock suggests prices could drop further, possibly providing another buying opportunity later.
Overall insider investment shows confidence in company's ops and finances, but shareholders advised not to use insider transactions as sole measure of potential investment value.
Stock's performance may signify internal challenges. Investors should ensure business quality before investing. The current downward shares trend amid profitability growth demands careful evaluation.
Despite National Vision Holdings reinvesting for growth, it may not become a multi-bagger. Market skepticism persists as earnings improvements from these investments may take time.
National Vision股票討論區
專欄Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
2023Q1營收增長6.6%,營業利潤繼續下滑10.7%,淨利潤下滑39.4%。
目前市盈率39.8,市盈率TTM提高到了51.8,如果按過去3年平均淨利6880萬計算,對應市盈率爲23.5,依然不低,目前缺乏投資價值。
TOP WATCH AH + 7/27 ⚡️
專欄Top upgrades and downgrades on 6/27: ETSY, CHWY, BBBY, GTLB and more
• $汽車地帶(AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy(CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision(EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $費森尤斯醫療(FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab(GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...
暫無評論